Related Experiment Video

Updated: Mar 19, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.1K

Sunitinib Possible Sex-Divergent Therapeutic Outcomes

Ignacio Segarra1, Pilar Modamio2, Cecilia Fernández2

  • 1Clinical Pharmacy and Pharmacotherapy Unit, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Barcelona, Avn. Joan XXIII, s/n, Barcelona, 08028, Spain. segarra100@gmail.com.

Clinical Drug Investigation
|June 20, 2016
PubMed

Insights

Sex differences may influence sunitinib treatment outcomes. Male patients might benefit more for kidney cancer, while females may fare better for brain tumors but experience more side effects.

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Research

Background:

  • Sunitinib, a tyrosine kinase inhibitor, treats renal cell carcinoma and metastatic brain tumors.
  • Preclinical studies indicate sex-divergent tissue pharmacokinetics for sunitinib.
  • Investigating sex-based pharmacokinetic differences may predict varied patient responses.

Purpose of the Study:

  • To explore potential sex-divergent therapeutic and toxicology responses to sunitinib in patients.
  • To correlate preclinical pharmacokinetic findings with clinical outcomes based on sex.

Main Methods:

  • Systematic review of scientific literature, including case reports, series, and clinical trials.
  • Analysis of studies associating patient sex with sunitinib treatment outcomes and adverse events.

Main Results:

  • Male patients may exhibit better response rates in renal cell carcinoma treatment.
  • Female patients might show improved outcomes in brain tumor treatment but higher adverse event incidence.
  • Preclinical data on sex-divergent tissue exposure align with observed clinical outcome trends.

Conclusions:

  • Sunitinib may have sex-divergent therapeutic effects in patients, consistent with preclinical pharmacokinetic data.
  • Further high-quality evidence is required to confirm these sex-based differences.
  • Systematic analysis of sex-based outcomes in clinical trials and ethical reviews is recommended to optimize patient care and trial design.

More Related Videos

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

2.9K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
536
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
316
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
327